— Round led by Avidity Partners with participation from Insight Capital, Mirae Asset Capital, and Alexandria Venture Investments, alongside participation from existing investors — — Investment will support ongoing clinical development of PARG inhibitor ETX-19477 and further advancement of pipeline — SAN DIEGO–(BUSINESS WIRE)–858 Therapeutics today announced it raised $50 million in a Series B… The post 858 Therapeutics Announces $50 Million Series B Financing appeared first on 8five8 Therapeutics .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules